FTC to Sue ‘Big Three’ PBMs for Setting Insulin, Other Drug Prices: WSJ 7/11/2024

FTC Ban That Would Make Switching Jobs Easier Hits Roadblock 7/11/2024

Syntis Bio Launches in Effort to Challenge GLP-1s in Lucrative Weight Loss Ma... 6/11/2024

Ipsen, Genfit’s Elafibranor Wins FDA Approval for Primary Biliary Cholangitis 6/11/2024

Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’ 6/11/2024

Stada Bags European Rights from Alvotech to Biosimilar of Amgen Blockbusters 6/11/2024

GSK Appeals Delaware Court’s Decision in Zantac Cases as Plaintiff Drops Lawsuit 6/11/2024

Lilly Sees More Zepbound Out-of-Pocket Payments as Obesity Pill Nears Phase III Readout 6/11/2024

Top 5 Companies Hiring in San Diego 4/11/2024

A new study from Karolinska Institutet in Sweden and the Chinese Academy of Medical Sciences has identified an RNA molecule that is important for skin wound healing. The research, published in Nature Communications, may have implications for the treatment of hard-to-heal wounds.

The study focuses on the molecular processes in wound healing that regulate the transition from inflammation - a critical defence mechanism - to a proliferative phase, where new cells form to repair damaged tissue.

Novo Nordisk today announced a new global initiative to prevent obesity in children. The Childhood Obesity Prevention Initiative aims to accelerate the prevention of childhood obesity in disadvantaged urban communities globally. Together with a coalition of partners such as city governments, academic institutions and non-profit organisations, the initiative will support six cities in designing, implementing and evaluating tailored solutions focused on physical activity and healthy eating.

Imagine a world where your own immune cells are transformed into cancer-fighting superheroes. This is the promise of CAR-T cell therapy, a groundbreaking treatment that’s already saving lives.

In this therapy, patients' own immune cells are collected, genetically engineered so that they specifically target cancer cells, then returned to the body. The result is a potent new option for battling blood cancers. However, as with any superhero journey, the process of harnessing this incredible power comes with its own set of challenges.

VC Firm Flagship Raises $3.6B to Create, Support 25 ‘Breakthrough’ Companies 7/10/2024

FDA Approves Atopic Dermatitis Label Expansion for Arcutis’ Zoryve Cream 7/10/2024

Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger 7/10/2024

Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data 7/10/2024

Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists 7/10/2024

Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors 7/10/2024

Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia 7/10/2024

Why Is Antimicrobial Resistance Not Getting Much Attention from Biopharma? 7/10/2024